MYD88 and colitis: rTsgal also alleviated DSS-induced murine colitis by inhibiting the TLR-4 (TLR-2)/MyD88/NF-κB signaling pathway, reducing excessive inflammatory responses, improving inflammatory cell infiltration and tissue damage [57].